Publications by authors named "Houda Sefiani"
In Morocco, chloroquine/hydroxychloroquine + azithromycin have been used off-label for COVID-19 treatment. This study aimed to describe the distribution, nature and seriousness of the adverse drug reactions (ADRs) associated with the two drug combinations in COVID-19 in-patients. We conducted a prospective observational study based on intensive pharmacovigilance in national COVID-19 patients' management facilities from April 1 to June 12, 2020.
View Article and Find Full Text PDFArticle Synopsis
- The COVID-19 pandemic, caused by SARS-CoV-2, has posed significant challenges to healthcare systems for over two years, prompting rapid global responses to manage its high morbidity and mortality rates.
- Despite advancements in understanding the virus and developing vaccines, misinformation (termed "infodemic") has complicated public perception and behavior regarding vaccine safety and efficacy.
- Effective risk communication strategies among health authorities, societies, and healthcare professionals are essential to manage public understanding and response during pandemics, ensuring better outcomes for future health crises.
Background: Pharmacovigilance centres (PVCs) in the World Health Organization (WHO) Programme for International Drug Monitoring have demonstrated their ability to detect preventable adverse drug reactions (ADRs) in their databases. In this field, there is no gold-standard method for detecting medication errors and evaluating ADR preventability. Therefore, we developed, from existing tools, a preventability assessment method: the 'P Method' (PM).
View Article and Find Full Text PDF